Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2010 1
2014 2
2015 1
2016 2
2018 1
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean midarm an (1,556 results)?
Assessing the validity and intra-observer agreement of the MIDAM-LTC; an instrument measuring factors that influence personal dignity in long-term care facilities.
Oosterveld-Vlug MG, Pasman HR, van Gennip IE, de Vet HC, Onwuteaka-Philipsen BD. Oosterveld-Vlug MG, et al. Health Qual Life Outcomes. 2014 Feb 11;12:17. doi: 10.1186/1477-7525-12-17. Health Qual Life Outcomes. 2014. PMID: 24512296 Free PMC article.
The aim of this study was to create the Measurement Instrument for Dignity AMsterdam-for Long-Term Care facilities (MIDAM-LTC) and to assess its validity and intra-observer agreement. METHODS: Thirteen items specific for the LTC setting were added to the earlier developed, …
The aim of this study was to create the Measurement Instrument for Dignity AMsterdam-for Long-Term Care facilities (MIDAM-LTC) and to …
Which characteristics of nursing home residents relate to factors influencing their dignity?
Oosterveld-Vlug MG, de Vet HC, Pasman HR, van Gennip IE, Willems DL, Onwuteaka-Philipsen BD. Oosterveld-Vlug MG, et al. Geriatr Nurs. 2016 Sep-Oct;37(5):365-370. doi: 10.1016/j.gerinurse.2016.05.002. Epub 2016 May 31. Geriatr Nurs. 2016. PMID: 27260110
Questionnaires containing the Measurement Instrument for Dignity AMsterdam - for Long-Term Care facilities (MIDAM-LTC) were administered to 95 nursing home residents, residing on the general medical wards of six nursing homes in the Netherlands. Associations between reside …
Questionnaires containing the Measurement Instrument for Dignity AMsterdam - for Long-Term Care facilities (MIDAM-LTC) were administe …
COVID-19, Moral Injury and the Bhagvad Gita.
Menon B, Narayan SK, Bhade S. Menon B, et al. J Relig Health. 2021 Apr;60(2):654-662. doi: 10.1007/s10943-021-01210-z. Epub 2021 Feb 26. J Relig Health. 2021. PMID: 33635446 Free PMC article.
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL. Chevallier P, et al. J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854573 Clinical Trial.
PURPOSE: To determine the antitumor activity and safety of a combination of gemtuzumab ozogamicin (GO), intermediate-dose cytarabine, and mitoxantrone (MIDAM) in patients with refractory or relapsed CD33(+) acute myeloid leukemia (AML). ...The overall, event-free, and dise …
PURPOSE: To determine the antitumor activity and safety of a combination of gemtuzumab ozogamicin (GO), intermediate-dose cytarabine, and mi …
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.
Bahashwan S, Moluçon-Chabrot C, Hermet E, Ravinet A, Douge A, Veronese L, Tchirkov A, Lemal R, Berger MG, Veyrat-Masson R, Tournilhac O, Bay JO, Guièze R. Bahashwan S, et al. Am J Hematol. 2019 Jan;94(1):E32-E35. doi: 10.1002/ajh.25332. Epub 2018 Nov 25. Am J Hematol. 2019. PMID: 30370957 Free article. No abstract available.
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Roland V, Mahé B, Juge-Morineau N, Dubruille V, Guillaume T, Vigouroux S, Moreau P, Milpied N, Garand R, Avet-Loiseau H, Harousseau JL. Chevallier P, et al. Leuk Res. 2005 Sep;29(9):1003-7. doi: 10.1016/j.leukres.2005.02.005. Epub 2005 Apr 8. Leuk Res. 2005. PMID: 16038726
We have used the dose of 9 mg/m(2) of mylotarg 4 days after the beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM) in 17 patients with refractory (n=4) or relapsed (n=13) AML. ...Although the dose of mylotarg given in combination with …
We have used the dose of 9 mg/m(2) of mylotarg 4 days after the beginning of a chemotherapy including intermediate-dose aracytin and mitoxan …
Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients.
Peterlin P, Guillaume T, Delaunay J, Mohty M, Garnier A, Mahe B, Dubruille V, Blin N, Voldoire M, Touzeau C, Chauvin C, Gastinne T, Béné MC, Le Gouill S, Moreau P, Chevallier P. Peterlin P, et al. Semin Hematol. 2016 Jul;53(3):216-7. doi: 10.1053/j.seminhematol.2016.06.001. Epub 2016 Jun 18. Semin Hematol. 2016. PMID: 27496314 No abstract available.